Literature DB >> 29078671

Use of autologous platelet rich plasma (PRP) in stopping massive hemoptysis at the Lung Center of the Philippines: a pilot study.

Armand Gregorio C Sarmiento1, Jose Luis J Danguilan1, Zenaida M Mariano1, Maria Teresa A Barzaga2.   

Abstract

BACKGROUND: The purpose of this study is to determine the effect of using autologous platelet rich plasma (PRP) in patients having massive hemoptysis within a period of one week.
METHODS: This is a prospective cohort study involving 20 consecutive patients admitted who met the criteria for massive hemoptysis from July to October 2011. After stabilizing the patient, fiberoptic bronchoscopy (FOB) was performed for localization of bleeding within 6 hours from diagnosis. A 50mL of blood was extracted from the patient whom was to be used for autologous PRP concentrate. After identifying the anatomic site of bleeding, autologous PRP concentrate was instilled on the affected bronchus and was allowed to stay for 5 minutes after instillation. Patients were then monitored from the time the bleeding stopped in the first 24 hours, 2 days and 7 days respectively.
RESULTS: Mean age of the study population with massive hemoptysis was 47 years old (SD 17.3). Majority of cases were male 18 out of 20 (90%) and smokers 14 (70%) with a normal BMI (75%). Identification of bleeding site was more commonly seen on the right upper lobe 9 out of 20 (45%). Overall, 14 out of 20 patients (70%) were reported to have stopped bleeding immediately. Subsequent hospital days showed that 8 out of 20 patients (40%) had no hemoptysis. However, one [1] post-tuberculosis (TB) bronchiectatic patient had recurrence of massive hemoptysis, approximately 250 mL per expectorate, expired within the 7 days observation and one patient had lobectomy on the 2nd day. The rest had non-massive hemoptysis wherein their expectorations were only streaks of blood. Moreover, there was one [1] patient who had recurrence of massive hemoptysis 1 week after autologous PRP infusion and was eventually intubated. Majority of the subjects, eleven [11] were diagnosed to have post-TB bronchiectasis. The rest of the patients were worked-up prior to operation.
CONCLUSIONS: Overall, it was observed that the use of autologous PRP was able to stop bleeding in 40% of the study population for 7 days. It is simple and easy to reproduce as it was directly extracted from the patient.

Entities:  

Keywords:  Massive hemoptysis; fiberoptic bronchoscopy (FOB); platelet rich plasma (PRP)

Year:  2017        PMID: 29078671      PMCID: PMC5637742          DOI: 10.21037/jovs.2017.05.09

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  5 in total

Review 1.  Current applications of platelet gels in facial plastic surgery.

Authors:  Sumeet Bhanot; James C Alex
Journal:  Facial Plast Surg       Date:  2002-02       Impact factor: 1.446

Review 2.  Intraoperative use of autologous platelet-rich and platelet-poor plasma for orthopedic surgery patients.

Authors:  Kathleen M Floryan; William J Berghoff
Journal:  AORN J       Date:  2004-10       Impact factor: 0.676

3.  Massive hemoptysis.

Authors:  J A Crocco; J J Rooney; D S Fankushen; R J DiBenedetto; H A Lyons
Journal:  Arch Intern Med       Date:  1968-06

4.  Treatment of hemoptysis patients by thrombin and fibrinogen-thrombin infusion therapy using a fiberoptic bronchoscope.

Authors:  T Tsukamoto; H Sasaki; H Nakamura
Journal:  Chest       Date:  1989-09       Impact factor: 9.410

5.  Effects of autologous platelet concentrate reinfusion after open heart surgery in patients with congenital heart disease.

Authors:  Takeshi Hiramatsu; Tohru Okamura; Yasuharu Imai; Hiromi Kurosawa; Mitsuru Aoki; Toshiharu Shin'oka; Yoshinori Takanashi
Journal:  Ann Thorac Surg       Date:  2002-04       Impact factor: 4.330

  5 in total
  1 in total

1.  Risks in Induction of Platelet Aggregation and Enhanced Blood Clot Formation in Platelet Lysate Therapy: A Pilot Study.

Authors:  Ying-Hao Wen; Chen-Fang Lee; Yu-Ju Chen; Gwo-Jyh Chang; Kowit-Yu Chong
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.